Medicilon Logo
search icon search icon language icon contact icon menu icon
Medicilon Logo
search icon close search icon language icon contact icon menu icon
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
Medicilon's News information
News information

Tau Protein Finding May Open Door to Novel Alzheimer’s Therapies

Page View:

Researchers at the University of California, Santa Barbara (UCSB) say they have advanced our understanding of how the tau protein, associated with Alzheimer’s disease, can morph from one physical state to another. In Alzheimer’s, tau aggregates to form ropelike inclusions within brain cells that eventually strangle the neurons. Until now, the team points out, how tau transitions from its soluble liquid state to solid fibers has remained unknown.

    Tau can, in a complex with RNA, condense into a highly compact “droplet” while retaining its liquid properties. During a process of phase separation, tau and RNA hold together, without the benefit of a membrane, but remain separate from the surrounding milieu. This novel state highly concentrates tau and creates a set of conditions in which it becomes vulnerable to aggregation.

The researchers published their study (“RNA Stores Tau Reversibly in Complex Coacervates”) in PLOS Biology.

“…prolonged residency within the droplet state eventually results in the emergence of detectable β-sheet structures according to thioflavin-T assay,” write the investigators. “These findings suggest that the droplet state can incubate tau and predispose the protein toward the formation of insoluble fibrils.”

“Our findings, along with related research in neurodegeneration, posit a biophysical ‘smoking gun’ on the path to tau pathology,” said Kenneth S. Kosik, M.D., UCSB’s Harriman Professor of Neuroscience and co-director of the campus’s Neuroscience Research Institute. “The signposts on this path are the intrinsic ability of tau to fold into myriad shapes, to bind to RNA, and to form compact reversible structures under physiologic conditions, such as the concentration, the temperature, and the salinity.”

The researchers found that, depending on the length and shape of the RNA, up to eight tau molecules bind to the RNA to form an extended fluidic assembly. Several other proteins like tau are known to irreversibly aggregate in other neurodegenerative diseases, such as amyotrophic lateral sclerosis, more commonly known as Lou Gehrig’s disease.

“There is an interesting relationship between intrinsically disordered proteins that are predisposed to become neurodegenerative—in this case tau—and this phase separation state,” said Song-I Han, Ph.D., a professor in UCSB’s department of chemistry and biochemistry. “Is this droplet stage a reservoir that protects tau or an intermediate stage that helps transform tau into a disease state with fibrils or both at the same time? Figuring out the exact physiological role of these droplets is the next challenge.”

Subsequent analysis will consist of an intensive search for the counterpart of tau droplets in living cells, according to the researchers. In future work, they also want to explore how and why a cell regulates the formation and dissolution of these droplets and whether this represents a potential inroad toward therapy.

Relevant newsRelevant news